secwatch.observer — SEC 8-K summary
======================================

Issuer:     RELMADA THERAPEUTICS, INC. (RLMD)
CIK:        0001553643
Form:       8-K
Filed at:   2023-01-17T23:59:59+00:00
Accession:  0001213900-23-002865
Event type: leadership
Sentiment:  neutral
Materiality: 0.25
Item codes: 1.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Relmada Therapeutics appoints Fabiana Fedeli to board of directors
------------------------------------------------------------------

- Board expanded from 5 to 6 members; Fedeli appointed Class I director effective Jan 12, 2023.
- Annual cash compensation: $66k as director, $9.9k audit committee, $7.7k compensation committee.
- Granted option to buy 200,000 shares at $4.22, vesting over 4 years, subject to shareholder approval.
- Fedeli is Chief Investment Officer at M&G Investments and was named in Financial News' 100 Most Influential Women in Finance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1553643/000121390023002865/0001213900-23-002865-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1553643/000121390023002865/ea171670-8k_relmada.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-002865

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer